SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

VRTX

VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Impact 2/10
Horizonimmediate Processed3d 22h ago SEC0001422848-26-000142
Passive stake amendment
Actionable Insight • Neutral

The incremental share increase is routine portfolio rebalancing by a large passive manager. No change in investment thesis; monitor next 13F for broader institutional positioning trends.

DirectionNeutral
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Capital Research Global Investors filed an amended Schedule 13G disclosing a 7.0% passive stake in Vertex Pharmaceuticals as of September 30, 2026, representing 17,821,661 shares. This is an increase from the prior filing (May 2026) which showed 17,794,137 shares, a net addition of approximately 27,524 shares. The filing confirms CRGI remains a passive investor with no control intent.

Key Financial Metrics

Stake
7%
Investor
Capital Research Global Investors
Investor Type
mutual fund

Key Facts

  • Capital Research Global Investors holds 17,821,661 shares of Vertex common stock as of September 30, 2026
  • Stake represents 7.0% of 253,460,924 shares outstanding
  • This is an amendment to Schedule 13G, indicating passive investment intent
  • Prior filing (May 2026) showed 17,794,137 shares; net increase of ~27,524 shares

Financial Impact

Stake valued at approximately $9.7B based on $138.7B market cap and 7.0% ownership

Risk Factors

  • Passive 13G filers may convert to 13D if they become activist, though no indication here
  • Large institutional ownership concentration (Capital Group entities combined hold significant stake) could amplify selling pressure if they reduce

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001422848-26-000142
Document: 0001422848-26-000142-index.html0001422848-26-000142
Document: 0001422848-26-000142.txt0001422848-26-000142

Track record

21 reports on VRTX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
  2. Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
  3. Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
  4. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $542.00 Now $531.45 −1.95% settles Nov 23
  5. Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
  6. Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
  8. Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
  9. Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
  10. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
Showing 10 of 21

US Market Status

Market Open · Closes in 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026